Definium Therapeutics, Inc.
DFTX
Rang in Aktien
#3577
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aktienkurs
$35.52
Marktkapitalisierung
$4.77B
Veränderung (1 Tag)
1.24%
Veränderung (1 Jahr)
181.04%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)
Kategorie
Healthcare
Kursverlauf für Definium Therapeutics, Inc. (DFTX)
Höchster Schlusskurs: $35.12 am 2026-10-01
Niedrigster Schlusskurs: $4.81 am 2016-11-01
Niedrigster Schlusskurs: $4.81 am 2016-11-01
Kursverlauf der Aktie von Definium Therapeutics, Inc. von 2016 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 98.59% |
| 2025 | 74.98% |
| 2024 | 107.98% |
| 2023 | 34.70% |
| 2022 | -89.90% |
| 2021 | -40.72% |
| 2020 | 7,946.66% |
| 2019 | -31.09% |
| 2018 | -81.58% |
| 2017 | -37.50% |
| 2016 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
